ProCE Banner Series

Paradigm Shifts in Hemophilia Prophylaxis: Putting Evidence Into Practice

Live satellite symposium on hemophilia with expert coverage of the latest clinical trial data on extended half-life factor replacement therapies and investigational nonfactor therapies seeking to restore the hemostatic balance through inhibition of antithrombin, tissue factor pathway inhibitor, or activated protein C.

Please note: You must be registered for the THSNA 2024 Conference to attend this symposium and simulcast. You may register at:

Who Should Attend

This educational program is intended for hematologists and other healthcare professionals who care for patients with hemophilia.

All Events

Paradigm Shifts in Hemophilia Prophylaxis: Putting Evidence Into Practice

Past Events




6:45 AM - 8:00 AM Central Time (CT)


Sheraton Grand Chicago, 301 E North Water Street, Chicago, Illinois 60611


ProCE Banner Faculty
Mark T. Reding, MD

Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

ProCE Banner Faculty
Angela C. Weyand, MD

Clinical Associate Professor of Pediatrics
Division of Hematology/Oncology
University of Michigan Medical School
Ann Arbor, Michigan

ProCE Banner Faculty
Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California


Registration and Breakfast:  6:45 AM - 7:00 AM CT

  • Welcome, Introduction, and Baseline Assessment
  • Current Treatment Paradigm for Hemophilia
  • Clinical Application of Advances in Factor Replacement Therapy
  • Clinical Implications on the Role of Novel Nonfactor Therapy to Improve Patient Outcomes
  • Panel Discussion and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.


Goal Statement
The goal of this program is to improve the knowledge, competence, and confidence of learners to optimally integrate new prophylactic therapies into the treatment paradigm for patients with hemophilia.

Target Audience
This educational program is intended for hematologists and other healthcare professionals who care for patients with hemophilia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Individualize prophylaxis for patients with hemophilia A with novel factor replacement therapies, considering available evidence, expert recommendations, and patient/caregiver preferences

  • Appraise the mechanisms by which new therapies for hemophilia A and B can restore hemostatic balance

  • Evaluate the available data for investigational nonfactor prophylaxis for hemophilia and their ability to improve patient outcomes without introducing new health risks

  • Integrate hemophilia therapies that aim to restore hemostatic balance into clinical practice as they become available


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


Provided by Clinical Care Options, LLC

Supported by an educational grant from Sanofi.